drugset / Trial / NCT02166268

Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber

NCT02166268 ↗

Phase 2 Completed 140 enrolled ALK-Abelló A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The clinical trial will investigate the efficacy of Avanz Phleum pratense in the treatment of rhinitis in an environmental challenge chamber.

Timeline

Start
2014-06
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator AVANZ Phleum pratense Unknown 15000 unknown Subcutaneous